What is Leerink Partnrs' Estimate for CTNM Q3 Earnings?

Key Points

• Leerink Partners forecasts that Contineum Therapeutics will report Q3 2025 earnings of ($0.67) per share, with a full-year estimate of ($2.01) per share.
• The company currently holds a Strong-Buy rating from Leerink Partners, with other analysts like Morgan Stanley recommending an "overweight" rating and setting a target price of $21.00.
• Contineum Therapeutics' stock has experienced a significant price range this year, with a low of $3.35 and a high of $20.24, and opened at $11.92 on Monday.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) - Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Contineum Therapeutics in a research note issued on Thursday, September 25th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.67) per share for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Contineum Therapeutics' current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Contineum Therapeutics' Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, Q1 2026 earnings at ($0.76) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($2.83) EPS.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.06).

CTNM has been the topic of a number of other research reports. Leerink Partners started coverage on shares of Contineum Therapeutics in a research note on Thursday. They set an "outperform" rating and a $20.00 target price on the stock. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. Finally, William Blair initiated coverage on shares of Contineum Therapeutics in a research note on Friday, June 20th. They issued an "outperform" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $22.20.

Contineum Therapeutics Stock Performance

CTNM opened at $11.92 on Monday. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $20.24. The firm's fifty day moving average is $9.04 and its 200 day moving average is $6.19. The stock has a market cap of $334.24 million, a price-to-earnings ratio of -5.42 and a beta of 1.13.

Institutional Trading of Contineum Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in Contineum Therapeutics in the 2nd quarter worth $45,000. Bridgeway Capital Management LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $76,000. Jane Street Group LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $81,000. RBF Capital LLC bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $159,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Contineum Therapeutics in the 2nd quarter worth about $43,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.